-$1.07 Earnings Per Share Expected for Audentes Therapeutics Inc (NASDAQ:BOLD) This Quarter

Analysts forecast that Audentes Therapeutics Inc (NASDAQ:BOLD) will announce earnings per share of ($1.07) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Audentes Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.98) and the lowest estimate coming in at ($1.21). Audentes Therapeutics reported earnings per share of ($0.97) during the same quarter last year, which would suggest a negative year over year growth rate of 10.3%. The company is scheduled to issue its next quarterly earnings report on Tuesday, November 5th.

On average, analysts expect that Audentes Therapeutics will report full year earnings of ($4.29) per share for the current year, with EPS estimates ranging from ($4.63) to ($3.97). For the next financial year, analysts expect that the business will report earnings of ($4.56) per share, with EPS estimates ranging from ($5.78) to ($3.39). Zacks’ EPS calculations are a mean average based on a survey of sell-side research firms that cover Audentes Therapeutics.

Audentes Therapeutics (NASDAQ:BOLD) last released its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($1.01) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.08) by $0.07. During the same quarter in the previous year, the firm posted ($0.85) earnings per share.

BOLD has been the subject of a number of research reports. Zacks Investment Research raised shares of Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Tuesday, October 8th. ValuEngine cut shares of Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 11th. Chardan Capital reissued a “buy” rating and issued a $50.00 price target on shares of Audentes Therapeutics in a research note on Sunday, October 6th. Mizuho reissued a “buy” rating and issued a $45.00 price target on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. Finally, William Blair reissued a “hold” rating on shares of Audentes Therapeutics in a research note on Wednesday, August 7th. Four research analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $39.35.

BOLD stock opened at $26.85 on Wednesday. Audentes Therapeutics has a one year low of $17.95 and a one year high of $41.65. The stock has a market cap of $1.22 billion, a PE ratio of -7.90 and a beta of 1.79. The firm has a 50 day simple moving average of $29.65 and a two-hundred day simple moving average of $35.57.

In other news, Director Louis G. Lange sold 10,000 shares of the company’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $32.16, for a total value of $321,600.00. Following the completion of the sale, the director now owns 276,044 shares of the company’s stock, valued at approximately $8,877,575.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew R. Patterson sold 20,000 shares of the company’s stock in a transaction on Monday, August 12th. The shares were sold at an average price of $34.04, for a total transaction of $680,800.00. Following the completion of the sale, the chief executive officer now directly owns 135,368 shares of the company’s stock, valued at approximately $4,607,926.72. The disclosure for this sale can be found here. 5.30% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Audentes Therapeutics by 14.2% during the 2nd quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock valued at $126,204,000 after buying an additional 413,768 shares during the period. Vanguard Group Inc. boosted its position in Audentes Therapeutics by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,971,206 shares of the biotechnology company’s stock valued at $74,629,000 after buying an additional 84,659 shares during the period. Victory Capital Management Inc. boosted its position in Audentes Therapeutics by 2.7% during the 2nd quarter. Victory Capital Management Inc. now owns 904,221 shares of the biotechnology company’s stock valued at $34,233,000 after buying an additional 23,620 shares during the period. D. E. Shaw & Co. Inc. boosted its position in Audentes Therapeutics by 118.6% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock valued at $22,449,000 after buying an additional 321,756 shares during the period. Finally, Northern Trust Corp boosted its position in Audentes Therapeutics by 3.1% during the 2nd quarter. Northern Trust Corp now owns 454,949 shares of the biotechnology company’s stock valued at $17,224,000 after buying an additional 13,685 shares during the period. 98.26% of the stock is owned by institutional investors.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Recommended Story: Compound Interest and Why It Matters When Investing

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News